Overview
Amelocerebrohypohidrotic syndrome, also known as Kohlschütter-Tönz syndrome (KTS), is a rare neurodegenerative disorder characterized by the combination of amelogenesis imperfecta (yellow-brown discoloration and abnormal enamel formation of the teeth), epilepsy, and intellectual disability. The condition was first described by Kohlschütter and colleagues in 1974. It primarily affects the central nervous system, teeth, and sweat glands (with reduced sweating or hypohidrosis being a variable feature). The syndrome typically presents in infancy or early childhood with seizures that may be difficult to control, progressive psychomotor regression or developmental delay, and characteristic dental enamel defects known as amelogenesis imperfecta, which gives the teeth a distinctly abnormal yellow-brown appearance. The condition is caused by mutations in the ROGDI gene (also referred to as leucine zipper-containing protein), located on chromosome 16p13.3. The ROGDI protein is believed to play a role in neuronal function, though its precise biological mechanism is not yet fully understood. The epilepsy associated with this syndrome can be severe and often refractory to standard antiepileptic medications. Affected individuals typically experience progressive cognitive decline and spasticity over time. There is currently no cure or disease-specific treatment for Kohlschütter-Tönz syndrome. Management is supportive and symptomatic, focusing on seizure control with antiepileptic drugs, dental care and restorative treatments for enamel defects, physical therapy, and developmental support. The prognosis varies but is generally guarded, with many patients experiencing significant neurological deterioration. Early diagnosis through clinical recognition of the triad of epilepsy, intellectual disability, and amelogenesis imperfecta, combined with genetic testing for ROGDI mutations, is important for appropriate management and genetic counseling.
Clinical phenotype terms— hover any for plain English:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Infantile
Begins in infancy, roughly 1 month to 2 years old
Treatments
No FDA-approved treatments are currently listed for Amelocerebrohypohidrotic syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Amelocerebrohypohidrotic syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Amelocerebrohypohidrotic syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Amelocerebrohypohidrotic syndrome.
Community
No community posts yet. Be the first to share your experience with Amelocerebrohypohidrotic syndrome.
Start the conversation →Latest news about Amelocerebrohypohidrotic syndrome
No recent news articles for Amelocerebrohypohidrotic syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Amelocerebrohypohidrotic syndrome
What is Amelocerebrohypohidrotic syndrome?
Amelocerebrohypohidrotic syndrome, also known as Kohlschütter-Tönz syndrome (KTS), is a rare neurodegenerative disorder characterized by the combination of amelogenesis imperfecta (yellow-brown discoloration and abnormal enamel formation of the teeth), epilepsy, and intellectual disability. The condition was first described by Kohlschütter and colleagues in 1974. It primarily affects the central nervous system, teeth, and sweat glands (with reduced sweating or hypohidrosis being a variable feature). The syndrome typically presents in infancy or early childhood with seizures that may be difficu
How is Amelocerebrohypohidrotic syndrome inherited?
Amelocerebrohypohidrotic syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Amelocerebrohypohidrotic syndrome typically begin?
Typical onset of Amelocerebrohypohidrotic syndrome is infantile. Age of onset can vary across affected individuals.